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ABSTRACT 
(less than 500 
words) 
 
Despite the increased knowledge of depression neurobiology, an effective 
improvement in the overall impact of pharmacotherapy is still lacking, possibly 
because a number of systems that are affected in mood disorders may not be 
adequately modulated by pharmacological treatments. Indeed, it is known that 
this complex disorder is characterized by the interaction of many factors of 
different nature -i.e. genetic, biological, social and environmental- that act in 
concert to lead to the development of the illness. Currently, there is strong 
evidence that depression involves alterations of the immune/inflammatory 
systems, thus pointing to the importance to characterize this association as well 
as evaluate the potential impact of pharmacological intervention to interfere 
with such alterations. On these bases, the purpose of our study was to analyze 
the cerebral expression of several mediators of the immune/inflammatory 
system in an animal model of depression based on the environmental 
component of the disease. Specifically, we used the well-established chronic mild 
stress (CMS) paradigm to develop a validated rat model of depression in order to 
elucidate the role of inflammation on the generation of the pathological 
anhedonic phenotype. Moreover, to evaluate the ability of the pharmacological 
treatment in modulating the behavioral-associated inflammatory alterations, 
rats exposed to CMS were also chronically treated with the antidepressants 
imipramine and with the antipsychotic lurasidone. Our findings indicate that the 
stress-induced anhedonic phenotype is associated to altered expression of 
specific mediators of immune/inflammatory system and that pharmacological 
treatment is not only able to normalize the anhedonic phenotype but also the 
inflammatory changes. These data suggest that immune/inflammatory alteration 
may contribute to the subject’s vulnerability of depression and support the idea 
that immune/inflammatory may serve as viable therapeutic target for more 
effective antidepressant drugs.  
 
 
